| Date | Subject | Details |
|---|---|---|
| 2025/03/10 | The Company’s board of directors resolvedto convene 2025 General Shareholder’s meeting | 20250310-3 |
| 2025/03/10 | The Board of Directors has resolved not to distributedividends | 20250310-2 |
| 2025/03/10 | The Company’s 2023 consolidated financial statements have been approved by the Board of Directors | 20250310-1 |
| 2025/03/03 | Announcement about resignation of the Company’s Chief Scientific Officer | 20250303 |
| 2025/02/27 | Announcement of the date of the board ofdirectors meeting for the fourth quarter of 2024financial report | 20250227 |
| 2025/02/02 | Reporting the Result of PI-initiated Phase IClinical Trial for OBP-301-Chemoradiation CombinationTherapy in ASCO (Corrected) | 20250202 |
| 2025/01/24 | Reporting the Result of PI-initiated Phase IClinical Trial for OBP-301-Chemoradiation CombinationTherapy in ASCO | 20250124 |
| 2025/01/15 | Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Changhua Christian Hospital | 20250115 |
